Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/591,743
Filing Date	Unassigned
First Named Inventor	Alley, Stephen C.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	018891-000720US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	12	US-2005/0152894 A1	07-14-2005	Krummen et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	13	WO	2006/034488	A2	03-30-2006	Eigenbrot et al.		☐
	14	WO	2006/065533	A2	06-22-2006	McDonagh et al.		☐
	15	WO	2006/065533	A3	06-22-2006	McDonagh et al.		☐
								☐
								☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/591,743
				Filing Date	Unassigned
				First Named Inventor	Alley, Stephen C.
				Art Unit	Unassigned
(Use as many sheets as necessary)				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	018891-000720US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	16	DORAL et al., "Role of Inter-Heavy and Light Chain Disulfide Bonds in the Effector Functions of Human Immunoglobulin IgG1," Molecular Immunology, 29(12):1487-1491 (1992).	☐
	17	FRANCISCO et al., " cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity," Blood, 102(4):1458-1465 (August 15, 2003).	☐
	18	GILLIES et al., "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," Hum. Antibod. Hybridomas, 1(1):47-54 (1990).	☐
	19	HAMANN et al., "Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody--Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia," Bioconjugate Chem., 13:47-58 (2002).	☐
	20	International Search Report of 8/17/2006 for International Application PCT/US05/07239.	☐
	21	LYONS et al., "Site-specific attachment to recombinant antibodies via introduced surface cysteine residues," Prot. Eng., 3(8):703-708 (1990).	☐
	22	OI et al., "Chimeric Antibodies," BioTechniques, 4(3):214-221 (1986).	☐
	23	Product description of Mylotarg® (gemtuzumab ozogamicin for Injection), by Wyeth Pharmaceuticals, Inc., 7/04 revision, pages 1-19.	☐
	24	QU et al., "Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates," J. Immunological Methods, 213:131-144 (1998).	☐
	25	RODWELL et al., "Site-specific covalent modification of monoclonal antibodies: *In vitro* and *in vivo* evaluations," PNAS, 83:2632-2636 (April 1986).	☐
	26	SAITO et al., "Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities," Advanced Drug Delivery Reviews, 55:199-215 (2003).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/591,743
				Filing Date	Unassigned
				First Named Inventor	Alley, Stephen C.
				Art Unit	Unassigned
(Use as many sheets as necessary)				*Examiner Name*	Unassigned
Sheet	3	of	3	*Attorney Docket Number*	018891-000720US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	27	STIMMEL et al., "Site-specific Conjugation on Serine -> Cysteine Variant Monoclonal Antibodies," J. Biol. Chem., 275(39):30445-30450 (2000).	☐
	28	SUN et al., " Reduction-Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides," Bioconjugate Chem., 16:1282-1290 (2005).	☐
	29	Written Opinion of 8/17/06 for International Application PCT/US05/07239.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.